PerfIL-17 Study: IL-17 Inhibitor Patterns, Persistence Among Patients with PsA
The real-world evidence study examined patients with PsA taking secukinumab and ixekizumab, highlighting 80% treatment persistence after 1 year.
Source: hcplive.com
Perfil 17 News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Perfil 17. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Perfil 17 Today - Breaking & Trending Today